MX2014006980A - Pirazol[1,5-a]piridina sustituida como inhibidores de la cinasa del receptor de tropomiosina (trk). - Google Patents
Pirazol[1,5-a]piridina sustituida como inhibidores de la cinasa del receptor de tropomiosina (trk).Info
- Publication number
- MX2014006980A MX2014006980A MX2014006980A MX2014006980A MX2014006980A MX 2014006980 A MX2014006980 A MX 2014006980A MX 2014006980 A MX2014006980 A MX 2014006980A MX 2014006980 A MX2014006980 A MX 2014006980A MX 2014006980 A MX2014006980 A MX 2014006980A
- Authority
- MX
- Mexico
- Prior art keywords
- trk
- pyridine
- inhibitors
- receptor kinase
- substituted pyrazolo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
La presente solicitud se refiere a una serie de compuestos sustituidos de pirazolo[1,5-a]piridina, su uso como inhibidores de la proteína cinasa de la familia (Trk) de la cinasa del receptor de tropomiosina, método de elaboración y composiciones farmacéuticas que comprenden tales compuestos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN4329CH2011 | 2011-12-12 | ||
PCT/IB2012/003012 WO2013088256A1 (en) | 2011-12-12 | 2012-12-12 | Substituted pyrazolo[1,5-a] pyridine as tropomyosin receptor kinase (trk) inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014006980A true MX2014006980A (es) | 2015-04-08 |
MX356401B MX356401B (es) | 2018-05-21 |
Family
ID=47902312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014006980A MX356401B (es) | 2011-12-12 | 2012-12-12 | Pirazol[1,5-a]piridina sustituida como inhibidores de la cinasa del receptor de tropomiosina (trk). |
Country Status (16)
Country | Link |
---|---|
US (7) | US9045479B2 (es) |
EP (2) | EP2791139B1 (es) |
JP (1) | JP5990595B2 (es) |
KR (2) | KR20140105508A (es) |
CN (1) | CN104114553B (es) |
AU (1) | AU2012351748B2 (es) |
BR (1) | BR112014014276A2 (es) |
CA (1) | CA2858958C (es) |
CL (1) | CL2014001529A1 (es) |
CO (1) | CO7071124A2 (es) |
DK (1) | DK2791138T3 (es) |
EA (1) | EA025352B1 (es) |
ES (1) | ES2686501T3 (es) |
IL (1) | IL233067B (es) |
MX (1) | MX356401B (es) |
WO (2) | WO2013088257A1 (es) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2738026C (en) | 2008-09-22 | 2017-01-24 | Array Biopharma Inc. | Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors |
PT2725028T (pt) | 2008-10-22 | 2016-08-31 | Array Biopharma Inc | Compostos de pirazolo[1,5-]pirimidina substituídos como intermediários na síntese de inibidores de cinase trk |
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
PL2918588T3 (pl) | 2010-05-20 | 2017-10-31 | Array Biopharma Inc | Związki makrocykliczne jako inhibitory kinazy TRK |
US9045479B2 (en) * | 2011-12-12 | 2015-06-02 | Dr. Reddy's Laboratories Ltd. | Substituted heterocyclic compounds as tropomyosin receptor kinase a (TrkA) inhibitors |
TWI663159B (zh) * | 2013-12-10 | 2019-06-21 | 美商健臻公司 | 原肌球蛋白相關之激酶(trk)抑制劑 |
CA2934010A1 (en) | 2013-12-20 | 2015-06-25 | Pfizer Limited | N-acylpiperidine ether tropomyosin-related kinase inhibitors |
CN103819343B (zh) * | 2014-02-17 | 2016-03-23 | 青岛农业大学 | 化合物2-烯丙基-4-氟-6-硝基苯酚的制备方法和农用生物活性 |
WO2015143652A1 (en) * | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
US20170197939A1 (en) | 2014-04-15 | 2017-07-13 | Pfizer Inc. | Tropomyosin-Related Kinase Inhibitors Containing Both A 1H-Pyrazole And A Pyrimidine Moiety |
WO2015170218A1 (en) | 2014-05-07 | 2015-11-12 | Pfizer Inc. | Tropomyosin-related kinase inhibitors |
WO2015169776A1 (en) * | 2014-05-08 | 2015-11-12 | Bayer Cropscience Ag | Pyrazolopyridine sulfonamides as nematicides |
US9394305B2 (en) | 2014-06-23 | 2016-07-19 | Dr. Reddy's Laboratories Ltd. | Substituted imidazo[1,2-a]pyridine compounds as tropomyosin receptor kinase a (TrkA) inhibitors |
WO2016009296A1 (en) | 2014-07-16 | 2016-01-21 | Pfizer Inc. | N-acylpiperidine ether tropomyosin-related kinase inhibitors |
WO2016020784A1 (en) | 2014-08-05 | 2016-02-11 | Pfizer Inc. | N-acylpyrrolidine ether tropomyosin-related kinase inhibitors |
KR102649887B1 (ko) | 2014-11-16 | 2024-03-22 | 어레이 바이오파마 인크. | (s)-n-(5-((r)-2-(2,5-디플루오로페닐)-피롤리딘-1-일)-피라졸로[1,5-a]피리미딘-3-일)-3-히드록시피롤리딘-1-카르복스아미드 히드로겐 술페이트의 결정질 형태 |
JP6606183B2 (ja) | 2014-12-18 | 2019-11-13 | ジェンザイム・コーポレーション | トロポミオシン関連キナーゼ(trk)阻害剤の医薬製剤 |
CN104672121B (zh) * | 2015-02-16 | 2017-10-24 | 上海华默西医药科技有限公司 | 2r‑(2,5‑二氟苯基)吡咯烷盐酸盐的制备方法 |
JP6564473B2 (ja) * | 2015-05-29 | 2019-08-21 | 无▲錫▼福祈制▲薬▼有限公司Wuxi Fortune Pharmaceutical Co.,Ltd | Janusキナーゼ阻害剤 |
CN108697708A (zh) | 2015-10-26 | 2018-10-23 | 洛克索肿瘤学股份有限公司 | Trk抑制剂抗性癌症中的点突变以及与此相关的方法 |
TN2018000335A1 (en) | 2016-04-04 | 2020-01-16 | Loxo Oncology Inc | Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
CN110049987B (zh) | 2016-05-18 | 2022-02-18 | 阵列生物制药公司 | 制备化合物及其盐的方法 |
JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
CA3041942C (en) | 2016-10-28 | 2023-03-14 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
JP7377718B2 (ja) * | 2017-05-12 | 2023-11-10 | エナンタ ファーマシューティカルズ インコーポレイテッド | アポトーシスシグナル調節キナーゼ1阻害剤およびその使用方法 |
US10246439B2 (en) | 2017-05-25 | 2019-04-02 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
US10253018B2 (en) | 2017-05-25 | 2019-04-09 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
WO2018218051A1 (en) | 2017-05-25 | 2018-11-29 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
US10738033B2 (en) | 2017-05-31 | 2020-08-11 | Nantbio, Inc. | Trk inhibition |
US10800760B2 (en) | 2017-05-31 | 2020-10-13 | Nantbio, Inc. | Trk inhibition |
CN109824566A (zh) * | 2017-07-19 | 2019-05-31 | 浙江师范大学 | 一种(r)-2-(2,5-二氟苯基)吡咯烷的合成方法 |
WO2019046186A1 (en) | 2017-08-28 | 2019-03-07 | Enanta Pharmaceuticals, Inc. | INHIBITORS OF KINASE 1 REGULATING THE APOPTOTIC SIGNAL CONTAINING TETRAZOLES AND METHODS OF USE THEREOF |
MA50456A (fr) | 2017-10-26 | 2020-09-02 | Array Biopharma Inc | Formulations d'un inhibiteur de kinase trk macrocyclique |
CN109867668B (zh) * | 2017-12-02 | 2021-03-26 | 广东东阳光药业有限公司 | 一种吡唑[1,5-a]吡啶化合物的晶型及其药物组合物和用途 |
CN109867671B (zh) * | 2017-12-02 | 2020-07-07 | 广东东阳光药业有限公司 | 一种吡唑[1,5-a]吡啶化合物的晶型及其药物组合物和用途 |
CN109867672B (zh) * | 2017-12-02 | 2020-07-07 | 广东东阳光药业有限公司 | 吡唑[1,5-a]吡啶衍生物的盐及其用途 |
US11179376B2 (en) * | 2017-12-20 | 2021-11-23 | Sunshine Lake Pharma Co., Ltd. | Salts of pyrazolo[1,5-a]pyridine derivative and use thereof |
CN108218754B (zh) * | 2018-01-23 | 2021-05-07 | 广东赛烽医药科技有限公司 | 一种2-(2,5-二氟苯基)吡咯烷的制备方法 |
CA3090376A1 (en) * | 2018-02-06 | 2019-08-15 | University Of Miami | Inhibitors of the notch transcriptional activation complex kinase ("nack") and methods for use of the same |
EP3773725A1 (en) | 2018-03-29 | 2021-02-17 | Loxo Oncology Inc. | Treatment of trk-associated cancers |
MX2020011225A (es) | 2018-05-02 | 2021-01-20 | Enanta Pharm Inc | Tetrazol que contiene inhibidores de la cinasa 1 reguladora de la señal de apoptosis y métodos de uso de los mismos. |
US10683289B2 (en) | 2018-05-02 | 2020-06-16 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
GB201811825D0 (en) | 2018-07-19 | 2018-09-05 | Benevolentai Bio Ltd | Organic compounds |
CN108794370A (zh) * | 2018-07-31 | 2018-11-13 | 上海弈柯莱生物医药科技有限公司 | 一种拉罗替尼中间体的制备方法 |
WO2020041417A1 (en) | 2018-08-22 | 2020-02-27 | Enanta Pharmaceuticals, Inc. | Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
GB201813791D0 (en) | 2018-08-23 | 2018-10-10 | Benevolental Bio Ltd | Organic compounds |
CN111171019A (zh) * | 2018-11-13 | 2020-05-19 | 上海轶诺药业有限公司 | 一类五元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途 |
WO2020106707A1 (en) | 2018-11-19 | 2020-05-28 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
CN109593802B (zh) * | 2018-12-24 | 2021-10-01 | 上海健康医学院 | 一种(r)-2-(2,5-二氟苯基)吡咯烷或其盐的制备方法 |
CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
WO2020198214A1 (en) | 2019-03-25 | 2020-10-01 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
CN110015980A (zh) * | 2019-05-14 | 2019-07-16 | 大连联化化学有限公司 | 一种合成叔丁基亚磺酰胺的方法 |
WO2020244614A1 (zh) * | 2019-06-05 | 2020-12-10 | 南京明德新药研发有限公司 | 吡咯并嘧啶类化合物及其应用 |
CN110751853B (zh) * | 2019-10-25 | 2021-05-18 | 百度在线网络技术(北京)有限公司 | 停车位数据的有效性识别方法和装置 |
EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
US20230399319A1 (en) * | 2019-12-27 | 2023-12-14 | Japan Tobacco Inc. | Acylsulfamide Compound and Pharmaceutical Use Therefor |
CA3163581A1 (en) | 2020-01-22 | 2021-07-29 | Benevolentai Bio Limited | Topical pharmaceutical compositions comprising imidazo[1,2-b]pyridazine compounds |
BR112022013156A2 (pt) | 2020-01-22 | 2022-10-18 | Benevolentai Bio Ltd | Composições farmacêuticas e seus usos |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
WO2021228248A1 (zh) * | 2020-05-15 | 2021-11-18 | 石药集团中奇制药技术(石家庄)有限公司 | 氮杂稠环酰胺类化合物及其用途 |
EP4188918A1 (en) * | 2020-07-29 | 2023-06-07 | Ideaya Biosciences, Inc. | Cyclized acetamido derivatives as dna polymerase theta inhibitors |
CN112979646B (zh) * | 2021-03-08 | 2022-01-14 | 北京富龙康泰生物技术有限公司 | 一种咪唑并吡啶类衍生物 |
WO2022234287A1 (en) | 2021-05-06 | 2022-11-10 | Benevolentai Bio Limited | Imidazopyridazine derivatives useful as trk inhibitors |
CN116115618A (zh) * | 2021-11-15 | 2023-05-16 | 石药集团中奇制药技术(石家庄)有限公司 | 一种***的药物 |
CN116120323A (zh) * | 2021-11-15 | 2023-05-16 | 石药集团中奇制药技术(石家庄)有限公司 | 固体形式的氮杂稠环酰胺类化合物及其用途 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0983244A1 (en) * | 1997-05-03 | 2000-03-08 | Smithkline Beecham Plc | Tetrahydroisoquinoline derivatives as modulators of dopamine d3 receptors |
JP2003231687A (ja) | 2002-02-04 | 2003-08-19 | Japan Tobacco Inc | ピラゾリル縮合環化合物及びその医薬用途 |
AU2003240488A1 (en) * | 2002-06-04 | 2003-12-19 | Neogenesis Pharmaceuticals, Inc. | Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents |
MXPA05000950A (es) | 2002-07-25 | 2005-05-16 | Pfizer Prod Inc | Derivados de isotiazol utiles como agentes anticancerosos. |
US7141568B2 (en) | 2003-07-09 | 2006-11-28 | Pfizer Italia S.R.L. | Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
JP2009518340A (ja) * | 2005-12-08 | 2009-05-07 | ノバルティス アクチエンゲゼルシャフト | EphBおよびVEGFR2キナーゼ阻害剤としてのピラゾロ[1,5−a]ピリジン−3−カルボン酸 |
US20100226881A1 (en) | 2007-07-11 | 2010-09-09 | Auckland Uniservices Limited | PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY |
CN102056927B (zh) | 2008-05-13 | 2014-06-25 | Irm责任有限公司 | 作为激酶抑制剂的稠合含氮杂环及其组合物 |
PT2725028T (pt) * | 2008-10-22 | 2016-08-31 | Array Biopharma Inc | Compostos de pirazolo[1,5-]pirimidina substituídos como intermediários na síntese de inibidores de cinase trk |
GEP20156285B (en) * | 2011-02-25 | 2015-05-11 | Aierem Elelsi | Compounds and compositions as trk inhibitors |
US9045479B2 (en) * | 2011-12-12 | 2015-06-02 | Dr. Reddy's Laboratories Ltd. | Substituted heterocyclic compounds as tropomyosin receptor kinase a (TrkA) inhibitors |
-
2012
- 2012-12-12 US US14/364,518 patent/US9045479B2/en not_active Expired - Fee Related
- 2012-12-12 CN CN201280069575.8A patent/CN104114553B/zh not_active Expired - Fee Related
- 2012-12-12 KR KR1020147018107A patent/KR20140105508A/ko active Application Filing
- 2012-12-12 EP EP12834589.9A patent/EP2791139B1/en not_active Not-in-force
- 2012-12-12 DK DK12832784.8T patent/DK2791138T3/en active
- 2012-12-12 WO PCT/IB2012/003022 patent/WO2013088257A1/en active Application Filing
- 2012-12-12 WO PCT/IB2012/003012 patent/WO2013088256A1/en active Application Filing
- 2012-12-12 EA EA201400701A patent/EA025352B1/ru not_active IP Right Cessation
- 2012-12-12 KR KR1020177000318A patent/KR101849143B1/ko active IP Right Grant
- 2012-12-12 US US14/364,451 patent/US9045478B2/en not_active Expired - Fee Related
- 2012-12-12 ES ES12832784T patent/ES2686501T3/es active Active
- 2012-12-12 AU AU2012351748A patent/AU2012351748B2/en not_active Ceased
- 2012-12-12 EP EP12832784.8A patent/EP2791138B1/en not_active Not-in-force
- 2012-12-12 CA CA2858958A patent/CA2858958C/en not_active Expired - Fee Related
- 2012-12-12 JP JP2014545388A patent/JP5990595B2/ja not_active Expired - Fee Related
- 2012-12-12 MX MX2014006980A patent/MX356401B/es active IP Right Grant
- 2012-12-12 BR BR112014014276A patent/BR112014014276A2/pt not_active IP Right Cessation
-
2014
- 2014-06-10 IL IL233067A patent/IL233067B/en active IP Right Grant
- 2014-06-11 CL CL2014001529A patent/CL2014001529A1/es unknown
- 2014-06-26 CO CO14137528A patent/CO7071124A2/es active IP Right Grant
-
2015
- 2015-02-26 US US14/632,078 patent/US9289419B2/en not_active Expired - Fee Related
- 2015-05-29 US US14/725,683 patent/US9402833B2/en active Active
-
2016
- 2016-05-25 US US15/164,430 patent/US9670207B2/en not_active Expired - Fee Related
-
2017
- 2017-06-01 US US15/611,203 patent/US10047087B2/en not_active Expired - Fee Related
-
2018
- 2018-08-13 US US16/101,753 patent/US10344031B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2014006980A (es) | Pirazol[1,5-a]piridina sustituida como inhibidores de la cinasa del receptor de tropomiosina (trk). | |
UA108926C2 (ru) | LibreOffice? [2,3-D] +" +" !+ | |
MX2010008719A (es) | Pirrolo [2,-d] piridinas y usos de las mismas como inhibidores de cinasa de tirosina. | |
GEP201706774B (en) | Heterocyclyl compounds | |
MX2015009950A (es) | Compuestos de imidazopiridina y sus usos. | |
WO2012007345A3 (en) | Substituted imidazo[1,2-a]pyrimidines and -pyridines | |
EA201290147A1 (ru) | Пирроло[2,3-d]пиримидиновые соединения | |
NZ703111A (en) | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases | |
MX2015010858A (es) | Formas solidas de un inhbidor de cdk4/6 selectivo. | |
BR112013011991A2 (pt) | composto, composição farmacêutica, uso de um composto, método de tratamento, produto, e kit. | |
ME01269B (me) | Jedinjenja pirolo (2,3-d) pirimidina | |
EA201300620A1 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-b]ПИРИДАЗИНА И ИМИДАЗО[4,5-b]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ JAK | |
MX342873B (es) | Derivados de pirazolo-quinazolina sustituidos como inhibidores de cinasa. | |
ZA201200982B (en) | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors | |
EA201000615A1 (ru) | Производные имидазо[1,2-а]пиридина, применимые в качестве ингибиторов апк (активиноподобной киназы) | |
MX2014000354A (es) | Quinazolinas sustituidas, su preparacion y su uso en composiciones farmaceuticas. | |
AU2012204982A8 (en) | 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as FAK/Pyk2 inhibitors | |
MX2012009074A (es) | Compuestos de urea pirrolo [2, 3-d] pirimidina como inhibidores de janus quinasa. | |
WO2013004995A8 (en) | Pyrimidinone compounds and their use | |
MX2014000635A (es) | Derivados de piridin-2(1h)-ona como inhibidores de jak. | |
EA201491376A1 (ru) | Производные 1h-пирроло[2,3-b]пиридина и их применение в качестве ингибиторов киназы | |
WO2010092015A8 (en) | Urea triazolo [1, 5-a] pyridine derivatives as pi3k inhibitors | |
WO2014053968A8 (en) | Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors | |
EA201291014A1 (ru) | Трициклическое индазольное соединение, способ его получения и содержащая его фармацевтическая композиция | |
MX2009007429A (es) | Compuestos de piridina y su uso como antagonistas de p2y12. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |